Abstract

The present invention provides: a neutral lipid capable of suppressing the phase transition of endosomal membranes caused by phosphatidylcholine from being inhibited; and a lipid nanoparticle containing said neutral lipid. The present invention pertains to an ionic neutral lipid comprising a compound represented by general formula (I). [In formula (I), R1 is a C1-22 hydrocarbon group; three R1's in one molecule may be the same group or different groups; a1 and a2 are each independently an integer of 0 to 4; b1 and b2 are 0 or 1, satisfying b1+b2=1; R2 and R3 are each independently a hydrogen atom or a C1-3 alkyl group; and R4 is an anionic group.]

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms

Abstract

The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7: and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)-(CH2)a-(O-CO)b-X (I) (R11)(R12)HC-(CH2)c-(CO-O)-(CH2)e-(A) -(CH2)d-N(R3)(R4) (B)

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C07C 219/06 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

A method for purifying a composition that comprises a step for dissolving the composition containing a compound represented by formula(1) [in formula (1): R1 represents -N(R2)-R2 (wherein R2 represents a C1-C4 alkyl group); R3 and R4 represent a C3-C8 alkanediyl group; R5 represents a hydroxyl group; R6 represents -R7-OH (wherein R7 represents a C4-C12 alkanediyl group) or a hydrogen atom; and n is an integer of 0 or 1] in an aqueous layer and performing liquid-liquid extraction, wherein an oil layer used in the liquid-liquid extraction contains one or more liquids selected from the group consisting of a ketone liquid, an ester liquid and an ether liquid each having a solubility parameter (SP value) of 14.8-20.5 (MPa1/2).

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 35/00 - Antineoplastic agents
• C07C 213/10 - SeparationPurificationStabilisationUse of additives
• C07C 219/06 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
• C07C 219/08 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
• C07C 227/40 - SeparationPurification
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention provides a pharmaceutical composition containing a compound that exhibits a coronavirus growth inhibitory activity. A pharmaceutical composition containing a compound represented by the formula (wherein: Y is N; R1 represents an optionally substituted aromatic heterocyclic group; R2 represents an optionally substituted 6-membered aromatic carbon ring group; R3 represents an optionally substituted aromatic heterocyclic group; -X- is -NH-; m is 0 or 1; R5a represents a hydrogen atom; R5b represents a hydrogen atom; n is 1; R4a represents a hydrogen atom; and R4b represents a hydrogen atom) or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a composition for promoting the regeneration of nucleus pulposus of intervertebral disc, said composition comprising a monovalent metal salt of a low endotoxin alginic acid and mesenchymal stem cells. In particular, the composition according to the present invention promotes the regeneration of nucleus pulposus of intervertebral disc via the activation of nucleus pulposus cells by human bone marrow-derived high-purity mesenchymal stem cells and/or the differentiation of human bone marrow-derived high-purity mesenchymal stem cells into nucleus pulposus cells.

IPC Classes  ?

• A61K 31/734 - Alginic acid
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61L 27/20 - Polysaccharides
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/58 - Materials at least partially resorbable by the body
• A61P 19/00 - Drugs for skeletal disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention provides an anti-viral agent and the like including a compound represented by general formula (1) or (2) (where R1 is -(CH2)n1-Z1-R11 or -CH-(-Z1-R11)2 (n1 is 0 or 1; Z1 is a single bond, -O-, -NH-, -S-, -SO-, -SO2-, -CO-, -CO-O-, or -CH=N-O-; R11 is a hydrogen atom, a C1-6 alkyl group, -NR12R13, -N3, -NO2, -CN, -CH2-CO-O-R14, or a nitrogen atom-containing 5-membered or 6-membered heterocyclic group; R12 and R13 are each independently a hydrogen atom or a C1-6 alkyl group; and R14 is a hydrogen atom or a C1-6 alkyl group; with the proviso that, in the heterocyclic group, a nitrogen atom in the ring group is linked to Z1) or a derivative thereof, a salt of these compounds, or a solvate of these.

IPC Classes  ?

• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61P 31/12 - Antivirals

Abstract

The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are useful as a drug substance, and a pharmaceutical composition containing the same. The compound represented by formula (1) or pharmaceutically acceptable salts thereof.

IPC Classes  ?

• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 31/14 - Antivirals for RNA viruses
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) [a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a straight-chain or branched-chain C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B) (d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group]. (I): (R1)(R2)C(OH)-(CH2)a-(O-CO)b-X. (A): (R11)(R12)-CH-(CO-O)c-(CH2)v-. (B): -(CH2)d-N(R3)(R4).

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention relates to a method for screening an anticancer agent by causing drosophila having the characteristics of a) expression of mutant Ras85D, b) deletion or suppressed expression of a p53 gene, c) overexpression of a cyclin E gene, and d) deletion or suppressed expression of a Med gene to ingest a test substance and comparing the survival rate thereof with the survival rate of drosophila that did not ingest the test substance. The present invention also relates to a combination drug of at least two kinase inhibitors for treatment of pancreatic cancer and to kinase inhibitors for use in said combination drug.

IPC Classes  ?

• A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/99 - Enzyme inactivation by chemical treatment
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

[Problem] The purpose of the present invention is to provide a modified adenovirus having a cytocidal activity on a target cell and high safety. [Solution] The present invention pertains to: a modified adenovirus which comprises an E1A gene, an enhancer sequence having a function of enhancing the expression of the E1A gene, and an AU-rich element introduced into the 3'-untranslated region of a viral gene, which is essentially required for the self-propagation thereof, or a position adjacent to the 3'-untranslated region, or a modified adenovirus which comprises an E1A gene and an enhancer sequence having a function of enhancing the expression of the E1A gene and cannot express normal E4orf6 protein, wherein the distance between the 5'-terminus of the E1A gene and the terminus of the enhancer sequence is 1500-4500 bp; and a medicine comprising the same.

IPC Classes  ?

• A61K 35/761 - Adenovirus
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/34 - Proteins from DNA viruses

Abstract

This power conversion device is provided with: a voltage detection means for detecting a common-mode voltage generated during a switching operation of a power semiconductor element; a voltage superposition means for superposing the common-mode voltage detected by the voltage detection means on an output of the power conversion device to cancel the common-mode voltage in a frequency equal to or higher than a switching frequency generated during the switching operation of the power semiconductor element; and a residual voltage detection means for detecting the common-mode voltage of the power conversion device superposed by the voltage superposition means. The voltage superposition means includes a feedback means for adding the common-mode voltage detected by the residual voltage detection means and superposing the added result on the output of the power conversion device. The voltage detection means comprises a first choke coil and a first capacitor.

IPC Classes  ?

• H02M 7/48 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode

Abstract

Provided is an expression vector for mammalian cells, which imparts to mammalian host cells a high-level production capability for a protein derived from a foreign gene. The amount of a desired protein that is produced in a transformant is increased by a plasmid DNA being incorporated into a transfer hotspot on the chromosome of a dihydrofolate reducing enzyme gene-deficient host cell, the foregoing being achieved by introducing a ubiquitously-acting chromatin opening element (UCOE) to an expression vector configured for selection of a strain that grows in a culture that does not contain hypoxanthine thymidine (hereinafter referred to as "HT").

IPC Classes  ?

• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/68 - Stabilisation of the vector
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

[Problem] To provide a partial oxidation catalyst that causes a light hydrocarbon partial oxidation reaction to proceed readily with high activity and high selectivity and a high-yield carbon monoxide production method using the same. [Solution] The invention is a light hydrocarbon partial oxidation catalyst containing a zeolite supporting cobalt and rhodium.

IPC Classes  ?

• B01J 29/24 - Iron group metals or copper
• B01J 29/46 - Iron group metals or copper
• B01J 29/76 - Iron group metals or copper
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• C01B 32/40 - Carbon monoxide

Abstract

Provided are: a new therapeutic strategy by using an inhibitor that targets PD-1/PD-L1; a pharmaceutical composition which contains a COX-2 inhibitor and is administered at any period of time prior to, subsequent to, or at the same time of the administering of the inhibitor targeting PD-1/PD-L1; and an immunostimulating effect enhancer which is for the inhibitor targeting PD-1/PD-L1 and contains a COX-2 inhibitor.

IPC Classes  ?

• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A lipid membrane structure contains, as a lipid component, a lipid compound represented by formula (I): (R1)(R2)C(OH)-(CH2)a-(O-CO)b-X [wherein a represents an integer of 3 to 5; b represents an integer of 0 or 1; R1 and R2 independently represent a linear hydrocarbon group that may have -CO-O-; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 independently represent a C1-4 alkyl group or a C2-4 alkenyl group, wherein R3 and R4 may be bonded together to form a 5- to 7-membered non-aromatic hetero ring (wherein one or two C1-4 alkyl groups or C2-4 alkenyl groups may be present as substituents on the ring))].

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• C07C 69/30 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
• C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
• C07D 295/03 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms

Abstract

Provided are: a flow channel structure with which lipid particles or micelles, which are useful as nano-sized carriers, for example, in drug delivery systems, are produced with good control of particle size; and a method for forming lipid particles or micelles using the same. Said flow channel structure has a two-dimensional structure such as one in which multiple structural elements (baffles) of a specified width are alternately disposed from the two side faces in a micro-sized flow channel through which feedstock solutions are flowed.

IPC Classes  ?

• B01J 13/04 - Making microcapsules or microballoons by physical processes, e.g. drying, spraying

Abstract

Provided is an anti-PD-L1 antibody capable of staining tumor cells such as melanoma. The anti-PD-L1 antibody comprises: (a) an L-chain which includes CDR1 having the amino acid sequence KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence SGS and CDR3 having the amino acid sequence QQHNEYPLT (SEQ ID NO: 2); and (b) an H-chain which includes CDR1 having the amino acid sequence GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, said composition comprising the anti-PD-L1 antibody as an active ingredient. Also provided is a method for producing the anti-PD-L1 antibody.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Provided is an anti-PD-L1 antibody that can be frequently administered to animals other than rats. The anti-PD-L1 antibody contains (a) an L-chain and (b) an H-chain. Said L-chain has: an L-chain-variable region including CDR1 that has the amino acid sequence QSLLYSENQKDY (SEQ ID NO: 37), CDR2 that has the amino acid sequence WAT, and CDR3 that has the amino acid sequence GQYLVYPFT (SEQ ID NO: 38); and an L-chain-constant region of an antibody of an animal other than a rat. Said H-chain has: an H-chain-variable region including CDR1 that has the amino acid sequence GYTFTSNF (SEQ ID NO: 39), CDR2 that has the amino acid sequence IYPEYGNT (SEQ ID NO: 40), and CDR3 that has the amino acid sequence ASEEAVISLVY (SEQ ID NO: 41); and an H-chain-constant region of an antibody of an animal other than a rat. A pharmaceutical composition comprising the anti-PD-L1 antibody as an active ingredient. A method of producing the anti-PD-L1 antibody is also provided.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/46 - Hybrid immunoglobulins
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies

Abstract

Provided is an anti-PD-1 antibody that can be administered frequently even to animals other than rats. An anti-PD-1 antibody including: (a) an L chain that has an L chain variable region including CDR1 having the amino acid sequence of QSLEYSDGYTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of GVS, and CDR3 having the amino acid sequence of FQATHDPDT (SEQ ID NO: 17), and also has an L chain constant region of an animal antibody other than rat; and (b) an H chain that has an H chain variable region including CDR1 having the amino acid sequence of GFSLTSYY (SEQ ID NO: 18), CDR2 having the amino acid sequence of IRSGGST (SEQ ID NO: 19), and CDR3 having the amino acid sequence of ARTSSGYEGGFDY (SEQ ID NO: 20), and also has an H chain constant region of an animal antibody other than rat. A pharmaceutical composition containing the anti-PD-1 antibody as an active ingredient. Also provided is a method for producing the anti-PD-1 antibody.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies

Abstract

Provided is an anti-LAG-3 antibody that can be frequently administered to a non-rat animal. The anti-LAG-3 antibody comprises: (a) an L chain comprising an L-chain variable region that includes CDR1 having a QSLLDSDGNTY (SEQ ID NO. 16) amino acid sequence, CDR2 having an SVS amino acid sequence, and CDR3 having an MQATHVPFT (SEQ ID NO. 17) amino acid sequence, and an L-chain constant region of a non-rat mammalian antibody; and (b) an H chain comprising an H-chain variable region that includes CDR1 having a GFDFDTYP (SEQ ID NO. 18) amino acid sequence, CDR2 having an ITIKTHNYAT (SEQ ID NO. 19) amino acid sequence, and CDR3 having an NREDFDY (SEQ ID NO. 20) amino acid sequence, and an H-chain constant region of a non-rat mammalian antibody. Also provided is a pharmaceutical composition containing the anti-LAG-3 antibody as an active ingredient. Also provided is a method of producing the anti-LAG-3 antibody.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 15/14 - Drugs for genital or sexual disordersContraceptives for lactation disorders, e.g. galactorrhoea
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 31/10 - Antimycotics
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies

Abstract

The present invention provides a composition for replenishing the nucleus pulposus of an intervertebral disc, the composition containing a monovalent metal salt of a low endotoxin alginic acid. The composition is applied to a nucleus pulposus site of a subject, is used to harden a part after application, and has fluidity when applied to the nucleus pulposus site. Accordingly, a composition for replenishing nucleus pulposus is provided, the composition being capable of promoting the regeneration of the nucleus pulposus of an intervertebral disc.

IPC Classes  ?

• A61K 31/734 - Alginic acid
• A61K 47/02 - Inorganic compounds
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61L 27/20 - Polysaccharides
• A61P 19/00 - Drugs for skeletal disorders

Abstract

A neutral monoclonal antibody useful for effective antibody therapy against Ebola virus is needed. The present invention provides a monoclonal antibody or antigen-binding fragment thereof that is capable of recognizing the GP internal membrane fusion loop of Ebola virus and neutralizing the biological activity of Ebola virus.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/02 - Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The purpose of the present invention is to provide a cationic lipid that can be used as a nucleic acid delivery carrier, a lipid membrane structure in which the cationic lipid is used, a nucleic-acid-introducing agent in which the cationic lipid is used, and a method for achieving nucleic acid introduction using the nucleic-acid-introducing agent containing the cationic lipid. The lipid membrane structure containing the cationic lipid represented by formula (1) (in the formula, each of the symbols is as defined in the specification) has exceptional stability in the blood and tumor accumulation properties. The nucleic-acid-introducing agent in which this cationic lipid is used makes it possible to achieve high nucleic acid delivery efficiency of a nucleic acid to be delivered into the cytoplasm.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• C07D 311/00 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings

Abstract

An object of the present invention is to provide a cationic lipid capable of achieving higher intracellular delivery efficiency than conventional cationic lipids, when used as a lipid membrane structure which is a carrier for delivering functional nucleic acid.A cationic lipid represented by the formula (1):(see formula 1)wherein each symbol is as defined in the present DESCRIPTION.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons

Abstract

The problem addressed by the present invention is to provide an object detection device that can infer the size of a moving object easily from an image. The object detection device (5) of an object detection system (1) has an object detection/determination unit (7) that analyzes the cycle of motion of an object from an image, and from the cycle of motion of the object, infers the size of the object.

IPC Classes  ?

• G01B 11/00 - Measuring arrangements characterised by the use of optical techniques

Abstract

The object of the present invention is to provide a method for preparing induced pluripotent stem cells from MAIT cells, and providing induced pluripotent stem cells derived from MAIT cells. Another object of the present invention is to provide a method for preparing MAIT-like cells from induced pluripotent stem cells, and providing MAIT-like cells. Differentiation of the induced pluripotent stem cells having a MAIT cell-specific TCR gene can be induced to establish MAIT-like cells.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided is a hydrogen storing carbon material with improved hydrogen storage capacity. The hydrogen storing carbon material has a total pore volume of at least 0.5 cm3/g, and the ratio of the total mesoporous volume to the total microporous volume per unit weight is at least 5. Moreover, the aforementioned hydrogen storing carbon material may have a nitrogen content of 0.5 wt% to less than 20 wt%. Furthermore, in an electrochemical measurement by chronopotentiometry in which the aforementioned hydrogen storing carbon material is used in a working electrode in the three-electrode method, when a cathode current is maintained at 1000 mA/g with respect to the aforementioned hydrogen storing carbon material, the stable potential may be -1.28 V or above.

IPC Classes  ?

• B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
• C01B 3/00 - HydrogenGaseous mixtures containing hydrogenSeparation of hydrogen from mixtures containing itPurification of hydrogen

Abstract

The present inventors conducted dedicated studies and successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired dihydrofolate reductase gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

As a result of dedicated research, the present inventors have successfully invented a collagen gene construct which can be easily purified and maintains a triple helix structure equivalent to that of naturally-occurring collagen while having a low molecular weight. Specifically, one-step purification by affinity purification is enabled because CR-D (a signal peptide) has a carbohydrate recognition domain. By substituting a portion of a human collagen structural gene of the present invention with the collagen-like structural gene portion of MBL, a low-molecular-weight collagen which maintains a triple helix structure and is thermally stable can be obtained with high purity and in large quantities.

IPC Classes  ?

• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C07K 19/00 - Hybrid peptides
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione